Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives
- 1 August 2015
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 101, 560-572
Abstract
No abstract availableKeywords
Funding Information
- Beijing Science Nova Program (2008B20)
- Central Universities (FRF-BR-14-002A)
This publication has 31 references indexed in Scilit:
- Structure–Activity Relationships of Tariquidar Analogs as Multidrug Resistance ModulatorsThe AAPS Journal, 2009
- Pharmacological Strategies for Overcoming Multidrug ResistanceCurrent Drug Targets, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinomaCancer, 2005
- Molecular mechanisms of drug resistanceThe Journal of Pathology, 2005
- Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacyEuropean Journal of Cancer, 2004
- The Role of ABC Transporters in Clinical PracticeThe Oncologist, 2003
- Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patientsBritish Journal of Cancer, 2001
- The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoproteinBritish Journal of Pharmacology, 1999
- Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivativesBioorganic & Medicinal Chemistry Letters, 1999